tm logo
Trademark Search
NAXIO

View On IC.GC.CA

NAXIO
CANCELLED

on 31 Dec 1969

Last Applicant/ Owned by

SOTIO BIOTECH INC.

180 Canal St. 3rd Flr.Boston MA 02114

US

Serial Number

2167017 filed on 21st Sep 2021

Registration Number

TMA1200515 registered on 27th Sep 2023

Registration expiry Date

21st Sep 2031

NAXIO

Trademark usage description

pharmaceutical products for the treatment of cancer or infectious diseases, namely, genetically engineered hematopoietic cells for the treatment of ca Read More

Classification Information

Class [005]
Pharmaceutical products for the treatment of cancer or infectious diseases, namely, genetically engineered hematopoietic cells for the treatment of cancer or infectious diseases; pharmaceutical preparations for cell therapy, namely, genetically engineered hematopoietic cells for the treatment of cancer or infectious diseases; biological preparations for cancer therapies and anti-infective therapies, namely, chimeric antigen receptors (CAR) and therapeutic preparations thereof, namely, viral vectors and plasmid vectors expressing CAR genes; therapeutic antibodies for use as immunotherapeutic agents for the treatment of cancer and infectious diseases; therapeutic T-cell receptors for use as immunotherapeutic agents for the treatment of cancer and infectious diseases; preparations for genetically modifying human or animal cells for medical purposes, including viral vectors and plasmid vectors.

Classification kind code

11

Class [042]
Industrial and scientific analysis in the field of pharmaceuticals and biotechnology, namely, in the field of genetically engineered hematopoietic cells, cell therapies, chimeric antigen receptors (CAR), therapeutic antibodies, therapeutic T-cell receptors, viral vectors and plasmid vectors; scientific research services in the field of pharmaceuticals and biotechnology, namely, genetically modifying human or animal cells to enable cells to be used for therapeutic purposes; scientific research in the development of cancer therapies or anti-infective therapies, namely, in the development of genetically engineered hematopoietic cells, cell therapies, chimeric antigen receptors (CAR), therapeutic antibodies, therapeutic T-cell receptors and viral vectors and plasmid vectors.

Classification kind code

11

Class [044]
Medical services in the field of extraction of human hematopoietic cells from patients and in the field of genetically modifying hematopoietic cells for therapeutic purposes; providing medical and therapy advice and consultancy in the field of medical therapies, namely, in the field of genetically engineered hematopoietic cells, cellular therapies, antibody therapies, and T-cell receptor therapies for the treatment of cancer or infectious diseases; providing information regarding the treatment of cancer and infectious diseases by means of a website, namely, in the field of treatment of cancer and infectious diseases by genetically engineered hematopoietic cells, cellular therapies, antibody therapies, and T-cell receptor therapies.

Classification kind code

11

Mark Details

Serial Number

2167017

Mark Type

Trademark

Legal History

Show more

Action TakenStatus
Submitted for opposition 26
on 09th Jun 2023		Approved
Submitted for opposition 27
on 09th Jun 2023		Approval Notice Sent
Submitted for opposition 22
on 05th Jun 2023		Search Recorded
Submitted for opposition 256
on 19th Dec 2022		Notification of Possible Opposition Sent
Submitted for opposition 135
on 05th May 2022		Amendment to Application
Submitted for opposition 257
on 17th Feb 2022		Designation Notification - Madrid Protocol
Submitted for opposition 1
on 17th Feb 2022		Created
Submitted for opposition 31
on 17th Feb 2022		Formalized
Submitted for opposition 228
on 21st Sep 2021		International Registration
Submitted for opposition 30
on 21st Sep 2021		Filed